bioAffinity Technologies, Inc. (BIAF)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.00M
Last updated: Nov 17, 2026 at 4:24 PM ET
bioAffinity Technologies, Inc. (BIAF) Statistics
bioAffinity Technologies (BIAF) has a market cap of $4.00M and an enterprise value of $1.63M. It kept -278.93% of revenue as net income over the last 12 months. It holds $2.37M more cash than debt, 59.22% of its market cap.
Total Valuation
Enterprise value is 59.22% below the market cap, as cash exceeds debt.
| Market Cap | $4.00M |
|---|---|
| Enterprise Value | $1.63M |
| Latest price (Nov 17, 2026) | $1.93 |
Key Dates
The next earnings report is expected on Mar 11, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 11, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.3x and 0.4x.
| P/S Ratio | 0.3x |
|---|---|
| Forward P/S | 0.5x |
| P/B Ratio | 0.4x |
| P/TBV Ratio | 0.9x |
Price Statistics
The stock is down 93.01% over 52 weeks and trades 61.09% below its 50-day average.
| Beta (1Y) | 2.01 |
|---|---|
| 52-Week Change | -93.01% |
| 1-Month Change | -45.01% |
| 3-Month Change | -68.54% |
| 6-Month Change | -92.43% |
| Total Return (1Y) | -93.01% |
| Total Return (3Y CAGR) | -85.44% |
| Return vs SPY (1Y) | -102.81% |
| Max Drawdown (1Y) | -97.29% |
| Max Drawdown (3Y) | -99.86% |
| Sharpe Ratio (1Y) | -1.33 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $4.96 |
| 200-Day Average | $18.23 |
| 52-Week Range | $1.96 to $80.70 |
| RSI (14 Days) | 29.8 |
| Average Volume (20 Days) | 90.85K |
Financial Position
Current assets cover 1.51x current liabilities, and total debt is 0.05x shareholder equity.
| Current Ratio | 1.51x |
|---|---|
| Quick Ratio | 1.47x |
| Debt / Equity | 0.05x |
| Interest Coverage | -306.74x |
Returns and Efficiency
Return on invested capital is -376.12% and return on equity is -393.69% over the last 12 months.
| Return on Equity (ROE) | -393.69% |
|---|---|
| Return on Assets (ROA) | -204.02% |
| Return on Invested Capital (ROIC) | -376.12% |
| Return on Capital Employed (ROCE) | -306.66% |
| Asset Turnover | 0.58x |
| Receivables Turnover | 6.75x |
Scores
BIAF has an Altman Z-Score of -20.48, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -20.48 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $5.53M over the last 12 months is down 18.47% from the 12 months before.
| Revenue | $5.53M |
|---|---|
| Revenue Growth (YoY) | -18.47% |
| Gross Profit | $5.53M |
| Operating Income | -$13.60M |
| Pretax Income | -$15.41M |
| Net Income | -$15.41M |
| EBIT | -$15.40M |
| Reported EPS (TTM) | -$15.85 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 51.79% of the $7.55M in total assets.
| Cash and Equivalents | $2.55M |
|---|---|
| Total Debt | $178.67K |
| Net Cash | $2.37M |
| Net Cash Per Share | $2.65 |
| Working Capital | $1.29M |
| Shareholder Equity | $3.91M |
| Book Value Per Share | $4.37 |
| Tangible Book Value | $1.84M |
| Tangible Book Per Share | $2.05 |
| Total Assets | $7.55M |
| Total Liabilities | $3.64M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $172.68K of capital spending, operating cash flow left -$13.03M of free cash flow.
| Operating Cash Flow | -$12.86M |
|---|---|
| Capital Expenditures | $172.68K |
| Free Cash Flow | -$13.03M |
| FCF Per Share | -$10.16 |
| Depreciation and Amortization | $366.57K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -246.14%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -246.14% |
| Pretax Margin | -278.87% |
| Net Margin | -278.93% |
| EBIT Margin | -278.64% |
| FCF Margin | -235.89% |
Dividends and Yields
BIAF does not pay a dividend. Its free cash flow yield is -753.47%.
| FCF Yield | -753.47% |
|---|---|
| Buyback Yield | -344.43% |
| Shareholder Yield | -344.43% |
Stock Splits
The last split was a 1-for-15 reverse split on Aug 24, 2026.
| Last Split Date | Aug 24, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 6 similar companies, BIAF has the 6th highest P/S.
P/S RatioPeer median 1.6x
ROICPeer median -14.34%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -50.00%
| P/S Ratio | 0.3x vs 1.6x median |
|---|---|
| ROIC | -376.12% vs -14.34% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -18.47% vs -50.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 18.58% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +18.58% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BIAF
What is BIAF's market cap?
bioAffinity Technologies has a market cap of $4.00M. Its enterprise value, which adds debt and subtracts cash, is $1.63M.
How many shares of BIAF are outstanding?
bioAffinity Technologies has 896.27K shares outstanding.
Does BIAF pay a dividend?
No. bioAffinity Technologies does not pay a dividend.
How much debt does BIAF have?
bioAffinity Technologies has $178.67K of total debt and $2.55M of cash and equivalents, a net cash position of $2.37M.
BIAF pages: Overview, Charting, Earnings, Financials, Statistics, Competitors